| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-982 | |
| Phytochemical name or plant extracts | Dehydrocorydaline | |
| PMID | 32377708 | |
| Literature evidence | It has been reported that DHC can inhibit the proliferation of breast cancer cells, however the underlying molecular mechanism remains elusive. | |
| IUPAC name | 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium | |
| Phytochemicals’ class or type of plant extracts | Alkaloid | |
| Source of phytochemicals or plant Extracts | Corydali syanhusuo | |
| Geographical availability | China South-Central, China Southeast | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | CDK1, CCND1, Bcl-2, MMP2, MMP9, Caspase 3, Caspase 8, Caspase 9, Bax, Bcl-2 | |
| Gene or Protein evidence | DHC exerted anticancer effects by downregulating cell proliferation, antiapoptosis, metastasis‑associated proteins CDK1, CCND1, BCL2 and metastasis‑associated proteins MMP2 and MMP9, and by upregulating the expression of proapoptotic proteins caspase 3/8/9. These results showed that dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Moreover, DHC inhibited the growth of MDA‑MB‑231 tumor xenografts in SCID mice, and decreased cell proliferation in newly formed tumors in vivo. | |
| Cell line/ mice model | MDA‑MB‑231 , MCF-7 | |
| Additional information | Western blotting assay showed that dehydrocorydaline dose-dependently increased Bax protein expression and decreased Bcl-2 protein expression. Furthermore, dehydrocorydaline induced activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9. | |
| PubChem ID | 34781 | |
| Additional PMIDs | 22298457 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:929107-1 | |
| Safety | NA |